Legal Representation
Attorney
Kimberly Jarman
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 15, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Jun 15, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 15, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Dec 1, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 1, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 1, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 1, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 17, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 16, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion and retinal disease; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion and retinal disease
First Use Anywhere:
0
First Use in Commerce:
0
Class 010
Sustained drug delivery systems for ocular drugs
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
010